Posts Tagged ‘Oncology’

Oncology: pale people may need vitamin D supplements due to low sun exposure

Cancer Causes and Control - 5th October 2011 10:19 pm

Fair-skinned people who burn quickly in the sun may need to take supplements to ensure they get the right amount of vitamin D, new research finds.

Cancer Research UK-funded researchers at the University of Leeds suggest that people with very pale skin may be unable to spend enough time in the sun to make the amount of vitamin D the body needs - while also avoiding sunburn.

The study, published in Cancer Causes and Control, suggested that melanoma patients may need vitamin D supplements as well.

But researchers also noted that sunlight and supplements are not the only factors that can determine the level of vitamin D in a person’s body.

Some inherited differences in the way people’s bodies process vitamin D into the active form also have a strong effect on people’s vitamin D levels.

The study defined the optimal amount of vitamin D required by the body as at least 60nmol/L.

Read more.

Oncology: Screening does not prevent prostate cancer deaths says study

Evidentia - 27th May 2011 10:03 am

Population-wide screening using the prostate-specific antigen (PSA) test would not help to reduce the number of deaths from prostate cancer, a 20-year Swedish study suggests.

PSA is a protein made by the prostate that is sometimes elevated in men with prostate cancer.

However, it is currently unreliable as a screening tool, as men with normal PSA levels can still have prostate cancer, while PSA may rise as a result of non-cancerous prostate conditions, sexual activity, infection or vigorous exercise in men who are cancer-free.

The latest research from Sweden’s Karolinska Institute provides further information to add to the ongoing debate.

Read more.

Oncology: patient survey adds weight to call for greater consensus on break through cancer pain

Evidentia - 18th November 2010 10:04 am

Experts are concerned that inadequate treatment strategies make cancer patients suffer unnecessarily.

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

The survey, which is the first international survey to look in detail at breakthrough cancer pain from a patient perspective, show that up to 45% of cancer patients experiencing breakthrough pain do not adhere to medication despite suffering from devastating episodes.

“The low adherence to drug therapy is a remarkable discovery and demonstrates that current treatments aren’t adequately meeting patients’ needs during these incapacitating episodes of pain,” explained Dr Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey.

The survey, moreover, found that up to 50% of patients seek additional help from non-pharmacological methods such as heat, positional changes and rest demonstrating the need for improved pain relief.

Read more.

Oncology: inadequate access to opioid-based pain relief is a human rights issue

Evidentia - 2nd November 2010 11:40 am

Many cancer patients in Europe are being denied access to adequate pain relief because of over-zealous regulations restricting the availability and accessibility of opioid-based drugs such as morphine.

Authors of the Europe-wide study say that restricting access to pain-killing drugs in this way is a breach of patients’ human rights, and they conclude that ‘there is an ethical and public health imperative to address these issues vigorously and urgently’.

The study, in the journal Annals of Oncology, is a joint report on the availability and accessibility of opioids for the relief of cancer pain by the European Society for Medical Oncology and the European Association for Palliative Care. The authors collected data from 21 Eastern European countries and 20 Western European countries.

Read more.

Longer term view of spending needed for chronic conditions

By Mike Broad - 28th September 2010 10:17 am

Ten health charities have produced a report calling on the NHS to take a long term view of spending on care for people with chronic conditions such as heart disease and cancer.

The report claims that too much money is wasted by focusing on short term savings rather than long term strategies, and it is vital that the needs of people with more than one chronic condition are met by the healthcare system.

The charities’ report, called How to deliver high quality, patient centred, cost effective care, identifies five key areas for improvement. They are:

1. Better co-ordinated care, which automatically includes long-term care planning with regular review. Too many people are currently admitted to hospital for conditions that could be effectively managed in the community.

2. Prevention, early diagnosis and intervention, which saves money as preventing or treating illness earlier means less need for more expensive intervention later.

3. Emotional, psychological and practical support. Long-term conditions can put people under severe psychological and emotional strain. Supporting people’s psychological health can help them manage their own condition and return to work.

4. Patients must be actively involved in decisions about their care. A major survey showed that this was what mattered most to patients about their care. It can improve the management of conditions and improve services.

5. Supported self-management. Patients should be treated more as able adults who are taught to manage their own conditions, rather than helpless patients who are forced to rely on healthcare professionals. They need to be given the tools to help themselves.

The charities behind the report are the British Heart Foundation, Age UK, Asthma UK, Breakthrough Breast Cancer, British Lung Foundation, Diabetes UK, Macmillan Cancer Support, Neurological Alliance, Rethink and the Stroke Association. They were helped by the King’s Fund.

They believe achieving these changes will require a policy and regulatory framework that is designed to support the delivery of patient-centred care. It will also require commitment, innovation and leadership from clinicians, managers and commissioners across the system. And it will require partnership in many forms; between patients and clinicians, and between different professions, organisations and sectors in health, social care, public health, wider public services, and the voluntary and private sectors.

It claims four specific recommendations are particularly important:

1. Greater accountability and rewards for patient-centred care.

2. Partnership between the public and voluntary sectors to spread best practice and innovation.

3. Commissioning that is informed by patients’ voices and insights.

4. Focus on co-ordinated care in commissioning and workforce planning.

The NHS, public health services and social care sectors need to be held properly accountable (and be rewarded) for providing services that meet these priorities, the report claims. To do this, accountability, standard-setting and payment systems such as the Outcomes Framework, the NICE quality standards and the tariff need to be structured around ensuring patient-centred care.

This, it suggests, can begin to be achieved by incorporating performance measures of the quality and cost of whole pathways of care that cross organisational boundaries, measuring care transitions, shared decision-making, access to information and self-management support, and reflecting the experiences, satisfaction and needs of patients with multiple conditions. If we continue to measure and reward organisations and services only in isolation from each other, and on the basis of limited dimensions of performance, it will remain very difficult to achieve the improvements in quality and value for money that we need.

Disseminating innovation is challenging in all industries, including health and social care. However, sharing evidence, information and examples of innovative, effective services and embedding innovation in the working culture of the NHS and social care is essential if we are to achieve change at pace and deliver consistently high-quality, cost-effective services across the country, the report claims.

Working with organisations such as NICE and NHS Evidence, and with the NHS Institute for Innovation and Improvement and its successors, the charities would like to help to share information about innovative services widely, to encourage and support NHS and social care leaders to adopt the ways of working and service models that they know work.

The decisions of commissioning boards, at the local, regional and national level, must be informed by patients’ experiences of care. The charities claim to have a wealth of intelligence on patients’ needs and experiences and are willing to offer advice and support to commissioners on all aspects of service design. Furthermore, if the government is to realise its commitment that there should be ‘no decision about me, without me’, the charities believe that all commissioning boards at national and regional level must have a significant, not tokenistic, number of members drawn from those representing patients, carers and voluntary organisations, and that all GP commissioning consortia must demonstrate significant patient involvement and input.

All patients with long-term conditions must have a right to choose a care-coordinator to oversee their care and act as a single contact point for the patient, the report asserts. This is an essential part of a health and social care service geared to deal with the burden of chronic disease in a way that is truly patient-centred and realises the cost and quality benefits of self-management. The charities say they are committed to supporting the relevant statutory authorities and professional bodies to ensure that these community-based roles and skills are developed. And they will also support commissioners to ensure that local needs assessments identify where failings in care co-ordination exist and provide advice to aid the commissioning of services that promote care co-ordination as part of programmes of care for patients.

Read the full report.

Oncology: breast cancer gene linked to ovarian cancer in Western Sweden

Evidentia - 6th August 2010 3:18 pm

A new study has shown a startling link between ovarian cancer and a rare gene mutation that causes breast cancer in a Swedish region with above average cancer rates.

Previous research has shown that women with breast cancer are more likely than other women to develop ovarian cancer. Now researchers from the Sahlgrenska Academy at the University of Gothenburg have shown that, in Western Sweden, only women with the mutation behind hereditary breast cancer run this increased risk of ovarian cancer.

Read more.

Oncology: dutasteride reduces prostate cancer risk in high-risk men

Evidentia - 22nd July 2010 4:21 pm

Dutasteride, already FDA-approved to shrink a benign, enlarged prostate, reduced the risk of a prostate cancer diagnosis by 23% in high-risk men in a large, international trial, researchers reported in a recent issue of the New England Journal of Medicine.

After four years, the investigators found that dutasteride significantly reduced the chances that men would be diagnosed with the tumours in the mid-range (requiring aggressive treatment). These are the majority of all prostate cancers and they grow unpredictably, leading many men to opt for surgery or radiation therapy. These treatments can cause incontinence and impotence.

Read more.

A report on the ‘seed and soil’ theory from San Antonio Breast Cancer Symposium 2009

Evidentia - 19th February 2010 8:43 pm

Dr Stephen Pagets in an article published in 1889, in The Lancet, wrote: “While many researchers have been studying the seed, the properties of the soil may reveal valuable insights into the metastatic peculiarities in cancer cases.”

After years of neglect, the field of bone biology is becoming attractive and hence researchers are giving full attention to the topic of bone health which was overdue. Breast cancer is commonly known to spread into the bones. Similarly, treatment for breast cancer can cause osteopenia and osteoporosis in many patients with normal bone.

Therefore, the use of bisphosphonates is commonly recommended in patients at risk of developing skeletal related events. At the recently held SABCS, there were many presentations on their mechanism of action and the role of bisphosphonates in the management of breast cancer.

Read more at Evidentia.